TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-08-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274

Prostatic Neoplasms

TERMINATED PHASE2

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409

Prostatic Neoplasms

COMPLETED PHASE2

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

NCT00766324

Metastatic Hormone Refractory Prostate Cancer

COMPLETED PHASE2

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00089856

Prostate Cancer

TERMINATED PHASE3

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

NCT00268710

Prostatic Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hormone Refractory Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Docetaxel Alone

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

Group Type ACTIVE_COMPARATOR

Docetaxel

Intervention Type DRUG

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

TroVax plus Docetaxel

Subjects will receive both TroVax plus 10 cycles of Docetaxel.

Group Type EXPERIMENTAL

Docetaxel

Intervention Type DRUG

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

TroVax

Intervention Type DRUG

Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Docetaxel

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

Intervention Type DRUG

TroVax

Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed \& dated written informed consent obtained from subject in accordance w/local regulations.
2. Histologically confirmed conventional and/or mucinous adenocarcinoma of the prostate. If histological confirmation is not available, cytological confirmation will be permitted in lieu.
3. Must meet one of following 3 criteria for progressive disease following androgen deprivation:

A. Subjects w/nodal or visceral metastases:

Must have progressive disease defined by RECIST criteria or defined by the Prostate Cancer Clinical Trials Working Group II (Scher et al. 2008).

B. Subjects w/no measurable disease:

PSA only disease must have an elevated PSA as defined by Consensus Criteria Prostate Cancer Clinical Trials Working Group II (Scher et al. 2008). PSA must indicate progressive disease defined as rising PSA values, at least 7 days apart, \>2 ng/mL in the 28 days prior to randomization.

C. Subjects w/bone involvement:

New disease on bone scan as defined by Consensus Criteria Prostate Cancer Clinical Trials Working Group II (Scher et al. 2008). 4. Subjects on stable dose of bisphosphonates showing subsequent tumor progression may continue on this medication; however, subjects are not allowed to initiate bisphosphonate therapy w/in 28 days prior to starting study treatment at Week 1 or at any time after that during the study, 5. Must be clinically immunocompetent. Clinical immunocompetence assumed unless subject has been diagnosed as immunosuppressed, is receiving immunosuppressive chemotherapy for oncology disorders, or is receiving immunosuppressive therapy following transplant, in which case they will be excluded.

6\. Subject free of clinically apparent/active autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, \& Rheumatoid Arthritis).

7\. Subject has adequate bone marrow function defined by Absolute Lymphocyte Count (ALC) ≥ 500/µL, Absolute Neutrophil Count (ANC) \>1200/µL, Platelet Count \>100,000/µL.

8\. Subject has peripheral neuropathy grade ≤1. 9. Subject has ECOG status of 0 or 1. 10. Minimum life expectancy ≥6 months. 11. Progressive disease (as defined above) must be documented after discontinuation of the hormonal and anti-androgen therapy.

12\. Subject continues to stay on medical treatment such as LHRH agonists or LHRH antagonists to maintain testosterone value of \<50ng/dL.

Exclusion Criteria

1. Subject has received prior chemotherapy for prostate cancer at any time. Subject has received chemotherapy for any other reason within five years of screening.
2. Subject is receiving any other hormonal therapy, including any dose of Megestrol Acetate, Finasteride, any herbal product known to decrease PSA levels (e.g., Saw Palmetto \& PC-SPES), or any systemic corticosteroid must discontinue agent for at least 4 weeks prior to the anticipated Week 1 visit. LHRH agonists or LHRH antagonists do not need to be discontinued.
3. Subject has started bisphosphonate or denosumab therapy less than 28 days before the anticipated Week 1 visit.
4. Subject is using supplements or complementary medicines/botanicals. Subjects should review label w/their doctor prior to enrolment. Exceptions to this exclusion:

* Conventional multivitamin supplements
* Selenium
* Lycopene
* Soy supplements
* Vitamin E
* Fish oil supplements
* Vitamin D
* Glucosamine supplements
* Age-related eye disease vitamins
* Ginkgo biloba
5. Subject has had major surgery or radiation therapy completed \<4 weeks prior to screening.
6. Corticosteroids are not permitted except for (a) nasal sprays and inhalers, (b) orally prescribed as replacement therapy in the case of adrenal insufficiency, (c) oral or IV dexamethasone administration used acutely in combination with docetaxel, (d) parenteral use on a single occasion, (e) low dose parenteral use for a maximum of 5 days and (f) acute and sporadic parenteral use for acute asthma.
7. Subject is known to test positive for HIV or hepatitis B or C.
8. Subject receiving concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents.
9. Subject has Platelet count \>400,000/μL; Monocytes \>80,000/μL; Haemoglobin \<11g/dL.
10. Subject has cerebral metastases (known from previous investigations or clinically detectable).
11. Subject has serum testosterone \>50ng/dL.
12. Subject has rheumatoid disease (asymptomatic subjects w/controlled \& rarely flaring rheumatoid arthritis are also excluded).
13. Subject exhibits evidence of symptomatic congestive heart failure, pulmonary embolus, vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable angina, myocardial infarction or active ischemia on ECG. If an ECG taken prior to screening but within 28 days of the anticipated Week 1 visit is not available, an ECG must be performed at screening.
14. Subject has uncontrolled severe hypertension \>150/100mm Hg (if controlled w/medication this is not an exclusion).
15. Subject is hypotensive.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No